PrecisemAb Awarded the Title of “2025 Emerging High-Potential Startup”
PrecisemAb Biotech has been honored by the Small and Medium Enterprise Administration, Ministry of Economic Affairs,…
Latest News
Read MorePrecisemAb Awarded the Title of “2025 Emerging High-Potential Startup”
PrecisemAb Impresses at US BIO and Bio Asia–Taiwan, Attracting Global Pharma Interest
PrecisemAb Biotech participated in the 2025 US BIO International Convention and Bio Asia–Taiwan, showcasing its Universal…
PrecisemAb Breaks Into the Final Six and Secures the Company First Prize at the 9th Startup Star Competition
PrecisemAb Biotech received the First Prize in the Company Category at the 9th Startup Star Pitch…
GlycoNex and PrecisemAb Co-Develop an Innovative Pro-Antibody Demonstrating High Tumor Selectivity and Safety; Research Published in an International Journal
PrecisemAb Biotech Co., Ltd. extends its sincere congratulations to the team at GlycoNex Inc.! We are…
Second Publication of 2025 Highlights PrecisemAb’s Advancement in Antibody Lock Technologies
We are excited to announce our second publication of the year.The study titled “Spatial-hindrance-based pro-Adalimumab prevents…
PrecisemAb Publishes New Research on Tumor-Selective Activation Antibodies in the International Journal of Biological Macromolecules
We are pleased to share that our latest research article,“Development of a tumor-region-selective activation monoclonal antibody…
Contact Us
+886 7 311 1577
｜Taipei office｜
17F, No. 3, Park St., Nangang Dist., Taipei City 115, Taiwan
｜R&D Center｜
12F, 1st Teaching Building, 100, Shih-Chuan 1st Rd., Sanmin Dist., Kaohsiung 807, Taiwan
